CTIS2023-508424-34-00Active, not recruitingPhase 1
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis - CNTO1959PSO3012
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Janssen Cilag International
- Enrollment
- 828
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •1. Male or female with at least 18 years of age., 2. Has a disease duration of plaque psoriasis of either =2 years or >2 years calculated from date at which first symptoms [plaque] were reported by subject to date of screening visit at screening; approximately 40% subjects must have a disease duration =2 years., 3. Has moderate-to-severe plaque-psoriasis defined by a) a PASI score >10 or affected BSA >10% and b) a DLQI score >10 at baseline (week 0)., 4. Is a candidate for systemic treatment for psoriasis., 5. Before first administration of study drug, a woman must be: a. Not of childbearing potential b. Of childbearing potential and practicing a highly effective method of contraception
Exclusion Criteria
- •1. clinical active psoriasis arthritis which needs systemic therapy beyond NSAIDs, 2. diagnosed or reported history or current signs or symptoms indicating severe, progressive, or uncontrolled hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, which are detected at screening assessments, 3. unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months, diagnosed or reported by the subject, 4. Has a transplanted organ, 5. history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type PsoriasisModerate to Severe Plaque Type PsoriasisMedDRA version: 20.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-001238-16-FRJanssen-Cilag International N.V.950
Completed
Phase 3
A Phase III, Clinical Trial to Evaluate the safety, tolerability and efficacy of 2 Fixed dose combinations of Azelnidipine and Chlorthalidone when compared with fixed dose combination of Amlodipine and Hydrochlorothiazide in patients with Stage II hypertension.CTRI/2020/03/023708Synokem Pharmaceuticals Ltd210
Active, not recruiting
Phase 1
A Phase 3, Randomized, Double-Blind, Parallell-Group, Multinational Trial of Intravenous Telavancin versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections due to Methicillin-Resistant Staphylococcus aureus. - ATTAIN 2EUCTR2004-002902-31-MTTheravance, Inc.746
Active, not recruiting
Phase 1
A study to compare SYN008 and Xolair for the treatment of chronic urticaria not well controlled by antihistaminesChronic spontaneous urticaria (Allergic asthma, Chronic rhinosinusitis with nasal polyps)MedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.1Level: PTClassification code 10080060Term: Chronic rhinosinusitis with nasal polypsSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-000149-42-HUSynermore Biologics Co., Ltd480
Terminated
Phase 3
A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi- centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add-On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and HypertensioDiabetes, Dyslipidemias, HypertensionSLCTR/2018/009Dr Shohini Ghosh